Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)
Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL
Sponsor: Astrum CRO, S.L.
A PHASE1 clinical study on Lymphoblastic T-Cell Lymphoma and T-cell Acute Lymphoblastic Leukemia, this trial is actively recruiting participants. The trial is conducted by Astrum CRO, S.L. and has accumulated 7 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1
-
Sep 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Mar 2023 — May 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astrum CRO, S.L.
- BioClever 2005 S.L.
- Hospital Clinic of Barcelona
- Hospital Sant Joan de Deu
- OneChain Immunotherapeutics
For direct contact, visit the study record on ClinicalTrials.gov .